The Covid-19 vaccine developed by Oxford University and the AstraZeneca company was 79% effective in preventing symptomatic disease in a large trial in the US, Chile and Peru, the company said today (Monday, March 22).
The vaccine proved 100% effective against serious or critical illness and hospitalization and is safe, the company said, publishing the results of a study of more than 32,000 volunteers in all age groups.
The data will give confidence to the British vaccine as the results of previous studies raised questions about the viability of the data.
It will also help clarify security questions, which has led to its suspension in some EU countries. After temporarily suspending the vaccine, several European countries resumed its use.
AstraZeneca stressed that the data do not show that the vaccine causes thrombosis of the cerebral venous sinus, which is a rare blood clot in the brain. Addressing the issue that has damaged trust in the vaccine in recent weeks, the company stresses that the vaccine does not cause blood clots.
- The new CDC rule says that this shorter distance is already safe for students in schools!
- The next categories to be vaccinated in the country after teachers
- Some European countries, such as Germany and Italy, plan to resume use of AstraZeneca
- The EMA makes the decision regarding the AstraZeneca vaccine
Sources: Guardian, CNBC
